Aurobindo Pharma Limited will invest up to USD 200 million on CapEx and over 5 percent of sale value on research and development (R&D) during the current financial year. The majority of the CapEx should be in terms of creating both finished dosage and API capacities. This includes formulation facility for derma.
Also, the company needs to expand API (active pharmaceutical ingredients) capacity with the growing need, as well as bringing certain APIs needed for the future. So from that perspective it would be a combination of both finished dosage and API expansion. The drug maker spent USD 225 million on CapEx last year and R&D expenditure was at Rs 872 crore or 4.5 percent of the revenues for the year.